Nose-to-brain delivery of tacrine.
In the treatment of Alzheimer's disease tacrine, a cholinesterase inhibitor, is not the drug of choice due to its low oral bioavailability, extensive hepatic first-pass effect, rapid clearance from the systemic circulation, pronounced hepatotoxicity, and the availability of drugs better than tacrine in the same pharmacological class. Hence, the aim of this investigation was to ascertain the possibility of direct nose-to-brain delivery of tacrine to improve bioavailability, to avoid the first-pass effect and to minimize hepatotoxicity. Tacrine solution (TS) in propylene glycol was radiolabelled with (99m)Tc (technetium) and administered in BALB/c mice intranasally (i.n.) and intravenously (i.v.). Drug concentrations in blood and brain were determined at predetermined time intervals post dosing. Drug targeting efficiency (DTE %) and the brain drug direct transport percentage (DTP %) were calculated to evaluate the brain targeting efficiency. Brain scintigraphy imaging in rabbits was performed to ascertain the uptake of the drug into the brain. Tacrine solution was effectively labelled with (99m)Tc and was found to be stable and suitable for in-vivo studies. Following intranasal administration tacrine was delivered quickly (T(max) 60 min) to the brain compared with intravenous administration (T(max) 120 min). The brain/blood ratios of the drug were found to be higher for [(99m)Tc]TS(i.n.) compared with [(99m)Tc]TS(i.v.) at all time points. The DTE (207.23%) and DTP (51.75%) following intranasal administration suggested that part of tacrine was directly transported to brain from the nasal cavity. Rabbit brain scintigraphy imaging showed higher uptake of the drug into the brain following intranasal administration compared with intravenous administration. The results showed that tacrine could be directly transported into the brain from the nasal cavity and intranasal administration resulted in higher bioavailability of drug with reduced distribution into non-targeted tissues. This selective localization of tacrine in the brain may be helpful in reducing dose, frequency of dosing and dose-dependent side effects, and may prove an interesting new approach in delivery of the drug to the brain for the treatment of Alzheimer's disease.
Jogani
Viral V
VV
Department of Pharmacy, Faculty of Technology & Engineering, The Maharaja Sayajirao University of Baroda, Post Box No. 51, Kalabhavan, Vadodara 390001, India.
Shah
Pranav J
PJ
Mishra
Pushpa
P
Mishra
Anil Kumar
AK
Misra
Ambikanandan R
AR
D000281:Administration, Intranasal; D000544:Alzheimer Disease / Q000188:drug therapy; D000818:Animals; D001682:Biological Availability; D001692:Biological Transport; D001812:Blood-Brain Barrier; D001921:Brain / Q000378:metabolism*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D004355:Drug Stability; D007275:Injections, Intravenous; D051379:Mice; D008807:Mice, Inbred BALB C; D019946:Propylene Glycol / Q000737:chemistry; D011817:Rabbits; D011877:Radionuclide Imaging; D011897:Random Allocation; D013619:Tacrine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D013667:Technetium; D013997:Time Factors; D014018:Tissue Distribution
D002800:Cholinesterase Inhibitors; D013619:Tacrine; D019946:Propylene Glycol; D013667:Technetium